Comment on “Prognostic significant of neutrophil: lymphocyte ratio, platelet – lymphocyte ratio, and lymphocyte: monocyte ratio in Kurdish patients with breast cancer”

WCRJ 2022; 9: e2427
DOI: 10.32113/wcrj_202211_2427

  Topic: Breast cancer     Category:

Dear Editor,

We read with great interest the article “Prognostic significant of neutrophil: lymphocyte ratio, platelet – lymphocyte ratio, and lymphocyte: monocyte ratio in Kurdish patients with breast cancer”1. In their analysis, Khazaei et al1, reported that serum inflammatory indicators as neutrophil, lymphocyte, platelet and relative ratio (neutrophil to lymphocyte ratio, derived neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio) had no significant influence on prognosis in patients with breast cancer1. In their manuscript, authors reported a lower overall survival rate of 5 and 10 years than women in other country1. This worst result is probably associated to a delay in diagnosis and consequently advanced breast cancer tumor staging due to lack of information, cultural differences and limited possible treatments1. Early diagnosis is one of the most influent prognostic factors, especially in the western country; therefore, the introduction of breast cancer screening led to a reduction in the incidence of advanced stage cancer, and it improved the overall survival2,3. Breast cancer survival has improved during the last decades, reaching about 87% at five years4. This outcome improvement, as reported in literature by many authors, is strongly correlated with breast cancer screening (considering both health policy organized screening and self-referral screening) 5,6. Diagnosis of early-stage breast cancer reduces the likelihood of involved lymph nodes allowing less invasive treatments in relation to the greater likelihood of local rather than systemic disease7. The advent of tailored and target therapy according to breast cancer predictive and prognostic factors contributes to achieve survival improvement8,9. Despite the identification of different subtype, the behavior of breast cancer is unpredictable, so even in women with same prognostic factors, a different clinical outcome is obtained1,10. In this context many researchers investigate novel cancer prognostic factors11. The role of inflammatory response in the progression and growth also in breast cancer is widely reported in literature 1. Reduction of post-operative surgical stress, as strategy to avoid immunological response impairment, is a modern tenet in oncological surgery with the aim of reducing early post-operative lymphopenia5,12. Avoidance of immunological response impairment is reported as possible benefit on oncological outcome but it is still debated in literature5. The key element between the immunological response and cancer progression has not been clearly identified 13 and biomarkers such as lymphocytes, neutrophils, have been suggested as possible cancer prognostic factors1. Correlations between immune biomarker and oncological outcome in breast cancer is contradictory1. In contrast with Khazaei et al1 analysis, some studies documented a significant association of neutrophil to lymphocyte ratio with worst disease-free survival and overall survival in breast cancer patients 1,14.

We strongly believe in the role of the immunological response in cancer patients15. All the measures to reduce surgical stress and immunological impairment should be preferred 5. In agreement with the authors, we believe that large prospective studies are needed; or probably these immunological biomarkers are not the factors that allow us to evaluate this impairment. Genetic or bioengineering studies will allow us to better understand this correlation or the pathway that allows cancer progression16.


Conflict of interest

The authors declare no conflict of interest




  1. Khazaei S, Tarlan M, Madani SH, Jalilian S. Prognostic Significant of Neutrophil: Lymphocyte Ratio, Platelet – Lymphocyte ratio, and Lymphocyte – Monocyte ratio in Kurdish Patients with breast cancer. WCRJ 2022; 9: e2365.
  2. Vanni G, Pellicciaro M, Materazzo M, Bruno V, Oldani C, Pistolese CA, Buonomo C, Caspi J, Gualtieri P, Chiaravalloti A, Palombi L, Piccione E, Buonomo OC. Lockdown of Breast Cancer Screening for COVID-19: Possible Scenario. In Vivo 2020; 34: 3047-3053.
  3. Vanni G, Tazzioli G, Pellicciaro M, Materazzo M, Paolo O, Cattadori F, Combi F, Papi S, Pistolese CA, Cotesta M, Santori F, Caspi J, Chiaravalloti A, Muscoli S, Lombardo V, Grasso A, Caggiati L, Raselli R, Palli D, Altomare V, D’Angelillo RM, Palombi L, Buonomo OC. Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients. Anticancer Res 2020; 40: 7119-7125.
  4. Buonomo OC, Materazzo M, Pellicciaro M, Caspi J, Piccione E, Vanni G. Tor Vergata University-Hospital in the Beginning of COVID-19-Era: Experience and Recommendation for Breast Cancer Patients. In Vivo 2020; 34: 1661-1665.
  5. Vanni G, Pellicciaro M, Materazzo M, Dauri M, D’angelillo RM, Buonomo C, De Majo A, Pistolese C, Portarena I, Mauriello A, Servadei F, Giacobbi E, Chiaravalloti A, Buonomo OC. Awake breast cancer surgery: strategy in the beginning of COVID-19 emergency. Breast Cancer 2021; 28: 137-144.
  6. Rizza S, Coppeta L, Grelli S, Ferrazza G, Chiocchi M, Vanni G, Bonomo OC, Bellia A, Andreoni M, Magrini A, Federici M. High body mass index and night shift work are associated with COVID-19 in health care workers. J Endocrinol Invest 2021; 44: 1097-1101.
  7. Orsaria P, Varvaras D, Vanni G, Pagnani G, Scaggiante J, Frusone F, Granai AV, Petrella G, Buonomo OC. Nodal status assessment in breast cancer: strategies of clinical grounds and quality of life implications. Int J Breast Cancer 2014; 2014: 469803.
  8. Caputo R, Cianniello D, Giordano A, Piezzo M, Riemma M, Trovò M, Berretta M, De Laurentiis M. Gene Expression Assay in the Management of Early Breast Cancer. Curr Med Chem 2020; 27: 2826-2839.
  9. Buonomo O, Cabassi A, Guadagni F, Piazza A, Felici A, Piccirillo R, Atzei GP, Cipriani C, Schiaroli S, Mariotti S, Guazzaroni MN, Cossu E, Simonetti G, Pernazza E, Casciani CU, Roselli M. Radioguided-surgery of early breast lesions. Anticancer Res 2001; 21: 2091-7.
  10. Dimitrov G, Atanasova M, Popova Y, Vasileva K, Milusheva Y, Troianova P. Molecular and genetic subtyping of breast cancer: the era of precision oncology. WCRJ 2022; 9: e2367.
  11. Roselli M, Guadagni F, Buonomo O, Belardi A, Ferroni P, Diodati A, Anselmi D, Cipriani C, Casciani CU, Greiner J, Schlom J. Tumor markers as targets for selective diagnostic and therapeutic procedures. Anticancer Res 1996; 16: 2187-92.
  12. Muraro E, Furlan C, Avanzo M, Martorelli D, Comaro E, Rizzo A, Fae’ DA, Berretta M, Militello L, Del Conte A, Spazzapan S, Dolcetti R, Trovo’ M. Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer. Front Immunol 2017; 8: 1476.
  13. Framarino-dei-Malatesta M, Derme M, Manzia TM, Iaria G, De Luca L, Fazzolari L, Napoli A, Berloco P, Patel T, Orlando G, Tisone G. Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature. Expert Rev Clin Immunol 2013; 9: 781-9.
  14. Berretta M, Facchini B.A, Garozzo D, Necci V, Taibi R, Torrisi C, Ficarra G, Bitto A. Adapted physical activity for breast cancer patients: shared considerations with two Olympic and world Italian sports champions Eur Rev Med Pharmacol Sci 2022; 26: 5393-5398.
  15. Pisconti S, Della Vittoria Scarpati G, Facchini G, Cavaliere C, D’Aniello C, Friscinni A, Melissano A, Bellini E, Perri F. The evolving landscape of immunotherapy against cancer. WCRJ 2018; 5: e1042.
  16. Peloso A, Katari R, Murphy SV, Zambon JP, DeFrancesco A, Farney AC, Rogers J, Stratta RJ, Manzia TM, Orlando G. Prospect for kidney bioengineering: shortcomings of the status quo. Expert Opin Biol Ther 2015; 15: 547-58.


To cite this article

Comment on “Prognostic significant of neutrophil: lymphocyte ratio, platelet – lymphocyte ratio, and lymphocyte: monocyte ratio in Kurdish patients with breast cancer”

WCRJ 2022; 9: e2427
DOI: 10.32113/wcrj_202211_2427

Publication History

Submission date: 04 Oct 2022

Revised on: 27 Oct 2022

Accepted on: 10 Nov 2022

Published online: 21 Nov 2022